利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.051 秒)

    Substituted pyridoindoles as serotonin agonists and antagonists
    3.
    发明授权
    Substituted pyridoindoles as serotonin agonists and antagonists 有权
    取代的吡啶并吲哚作为血清素激动剂和拮抗剂

    公开(公告)号：US06699852B2

    公开(公告)日：2004-03-02

    申请号：US10026611

    申请日：2001-12-19

    申请人： Albert Robichaud ,  John M. Fevig ,  Ian S. Mitchell ,  Taekyu Lee ,  Wenting Chen ,  Joseph Cacciola

    发明人： Albert Robichaud ,  John M. Fevig ,  Ian S. Mitchell ,  Taekyu Lee ,  Wenting Chen ,  Joseph Cacciola

    IPC分类号： A61K3133

    CPC分类号： C07D471/16 ,  C07D498/16 ,  C07D513/16

    摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

    摘要翻译： 本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6，R 7，R 8，R <9>，X，b，k和n，这里描述虚线。 本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症 ，以及胃肠道疾病如胃肠道运动功能障碍。

    Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands
    4.
    发明授权
    Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands 有权
    取代的吡嗪喹喔啉衍生物作为血清素受体激动剂和拮抗剂配体

    公开(公告)号：US06638934B2

    公开(公告)日：2003-10-28

    申请号：US10026404

    申请日：2001-12-19

    申请人： Albert Robichaud ,  Ian S. Mitchell ,  Taekyu Lee ,  Wenting Chen

    发明人： Albert Robichaud ,  Ian S. Mitchell ,  Taekyu Lee ,  Wenting Chen

    IPC分类号： C07D48702

    CPC分类号： C07D487/04

    摘要： The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R4b, R5, R6, R7, R8, R9, n, and X are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

    摘要翻译： 本发明涉及由结构式（I）和（Ia）表示的新化合物：或其药学上可接受的盐，其中R 1，R 4a，R 4b，R 5， R 6，R 7，R 8，R 9，n和X如本文所述。 本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠和性障碍，偏头痛和与头痛相关的其他病症，社交恐怖症 ，以及胃肠道疾病如胃肠道运动功能障碍。

    Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
    8.
    发明授权
    Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists 有权
    取代三环γ-咔啉作为血清素受体激动剂和拮抗剂

    公开(公告)号：US07109339B2

    公开(公告)日：2006-09-19

    申请号：US10743449

    申请日：2003-12-19

    申请人： Taekyu Lee ,  Wenting Chen ,  Wei Deng ,  Albert J. Robichaud ,  Ruth R. Wexler

    发明人： Taekyu Lee ,  Wenting Chen ,  Wei Deng ,  Albert J. Robichaud ,  Ruth R. Wexler

    IPC分类号： C07D417/00 ,  C07D471/04

    CPC分类号： C07D471/04

    摘要： The present invention is directed to novel compounds represented by structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R5, R6, R7, R8, R9,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.

    摘要翻译： 本发明涉及由结构式（I）表示的新化合物或其药学上可接受的盐，其中R 1，R 4a，R 5， R 6，R 6，R 7，R 8，R 9和M如本文所定义 。 本发明还涉及包含这些新化合物作为活性成分的药物制剂以及新型化合物及其制剂在治疗某些中枢神经系统疾病中的用途。 本发明的化合物是5-羟色胺受体调节剂，特别是5HT 2C受体激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括肥胖症，厌食症，血症，抑郁症，焦虑症， 精神病，精神分裂症，偏头痛，成瘾行为，强迫症和性功能障碍。

    Substituted heterocycle fused gamma-carbolines
    10.
    发明授权
    Substituted heterocycle fused gamma-carbolines 有权
    取代的杂环稠合的γ-咔啉

    公开(公告)号：US06713471B1

    公开(公告)日：2004-03-30

    申请号：US09594954

    申请日：2000-06-15

    申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Simon Haydar ,  Wenting Chen ,  Christopher D. Mc Clung ,  Emilie J. B. Calvello ,  David M. Zawrotny

    发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Simon Haydar ,  Wenting Chen ,  Christopher D. Mc Clung ,  Emilie J. B. Calvello ,  David M. Zawrotny

    IPC分类号： C07D26722

    CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

    摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

    摘要翻译： 本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6a，R 6b，R 7，R 7， <8>，R 9，X，b，k，m和n，这里描述虚线。 本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症 ，以及胃肠道疾病如胃肠道运动功能障碍。